<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00003678</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000066779</org_study_id>
    <secondary_id>CRC-TU-ATTOM</secondary_id>
    <secondary_id>EU-98042</secondary_id>
    <secondary_id>ISRCTN17222211</secondary_id>
    <nct_id>NCT00003678</nct_id>
  </id_info>
  <brief_title>Tamoxifen in Treating Women With Breast Cancer</brief_title>
  <official_title>A Large, Uniquely Simple, Randomised Study to Assess Much More Reliably the Balance of Benefits and Risks of Prolonging Adjuvant Tamoxifen Treatment in Early Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Birmingham</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using&#xD;
      tamoxifen may fight breast cancer by blocking the uptake of estrogen by the tumor cells.&#xD;
&#xD;
      PURPOSE: Randomized phase III trial to compare the effectiveness of at least 2 years of&#xD;
      tamoxifen with that of 5 additional years of tamoxifen in treating women who have breast&#xD;
      cancer that has been surgically removed.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Compare the disease-free and overall survival of women with early breast cancer who are&#xD;
           randomized to discontinue adjuvant tamoxifen vs those randomized to continue for at&#xD;
           least 5 additional years.&#xD;
&#xD;
      OUTLINE: This is a randomized study. Patients are stratified for analysis according to&#xD;
      duration of tamoxifen given before randomization (2-3 years vs 4-5 years vs 6-7 years vs 8-9&#xD;
      years vs 10 years and over), age (less than 49 vs over 50), and important prognostic factors,&#xD;
      including tumor type and grade and nodal and estrogen receptor status. Patients are&#xD;
      randomized to 1 of 2 treatment arms.&#xD;
&#xD;
        -  Arm I: Patients discontinue tamoxifen after at least 2 years of prior treatment.&#xD;
&#xD;
        -  Arm II: Patients continue treatment with tamoxifen for at least 5 additional years in&#xD;
           the absence of unacceptable toxicity or disease progression.&#xD;
&#xD;
      Patients are followed annually.&#xD;
&#xD;
      Peer Reviewed and Funded or Endorsed by Cancer Research UK&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 8,000-20,000 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>May 1991</start_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>All-cause mortality</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease recurrence</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death due to breast cancer, other primary tumors, or cardiovascular causes</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">20000</enrollment>
  <condition>Breast Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tamoxifen citrate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>adjuvant therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed breast carcinoma that has been completely excised&#xD;
&#xD;
               -  Clinically relapse free&#xD;
&#xD;
          -  Must have completed at least two years of adjuvant therapy with tamoxifen for early&#xD;
             breast cancer AND have no clear indication for or against receiving further tamoxifen&#xD;
&#xD;
          -  No significant endometrial hyperplasia&#xD;
&#xD;
          -  No patients with negligibly low risk of breast cancer death&#xD;
&#xD;
          -  Hormone receptor status:&#xD;
&#xD;
               -  Any status allowed&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Sex:&#xD;
&#xD;
          -  Female&#xD;
&#xD;
        Menopausal status:&#xD;
&#xD;
          -  Any status allowed&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No other life threatening disease&#xD;
&#xD;
          -  No retinopathy&#xD;
&#xD;
          -  No psychiatric disorder or other condition that would preclude study compliance&#xD;
&#xD;
          -  No serious toxicity (e.g., depression) thought to be due to tamoxifen&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Any primary treatment allowed&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel Rea, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University Hospital Birmingham</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cancer Research UK Clinical Trials Unit - Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>England</state>
        <zip>B15 2TT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <reference>
    <citation>Gray R, Davies C, Perry P. Tamoxifen for early breast cancer: better late than never. Ann Oncol. 2000 May;11(5):505-7. doi: 10.1023/a:1008323116265. No abstract available.</citation>
    <PMID>10907940</PMID>
  </reference>
  <reference>
    <citation>Rea D, Poole C, Gray R. Adjuvant tamoxifen: how long before we know how long? BMJ. 1998 May 16;316(7143):1518-9. doi: 10.1136/bmj.316.7143.1518. No abstract available.</citation>
    <PMID>9582148</PMID>
  </reference>
  <reference>
    <citation>Earl H, Gray R, Kerr D, Lee M. The optimal duration of adjuvant tamoxifen treatment for breast cancer remains uncertain: randomize into aTTom. Clin Oncol (R Coll Radiol). 1997;9(3):141-3. doi: 10.1016/s0936-6555(97)80067-2. No abstract available.</citation>
    <PMID>9269542</PMID>
  </reference>
  <reference>
    <citation>Earl H, Baker P, Kerr D, Lee M, Gray R, Baum M. Adjuvant treatment with tamoxifen. Recruitment into studies assessing optimum duration of treatment must continue. BMJ. 1996 Apr 20;312(7037):1036-7. doi: 10.1136/bmj.312.7037.1036b. No abstract available.</citation>
    <PMID>8616358</PMID>
  </reference>
  <reference>
    <citation>Gray R. Tamoxifen: how boldly to go where no women have gone before. J Natl Cancer Inst. 1993 Sep 1;85(17):1358-60. doi: 10.1093/jnci/85.17.1358. No abstract available.</citation>
    <PMID>8350355</PMID>
  </reference>
  <verification_date>March 2007</verification_date>
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>December 18, 2013</last_update_submitted>
  <last_update_submitted_qc>December 18, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 19, 2013</last_update_posted>
  <keyword>stage I breast cancer</keyword>
  <keyword>stage II breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tamoxifen</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

